Bradley A. McGregor

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 598 citations · Full text

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi, Meng Xiao He, Ziad Bakouny et al. · Cancer Cell · 2021 · 583 citations · Full text

Immunology, Immune Cell Therapy, Immunotherapy +16

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

David A. Braun, Kelly Street, Kelly P. Burke et al. · Cancer Cell · 2021 · 483 citations · Full text

Progressive Immune Dysfunction, Urology, Cancer Immunosurveillance +12

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy D. Gilligan, Daniel W. Lin, Rahul Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 440 citations

Surgical Oncology, Cancer Management, Gynecology +17

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Aly‐Khan A. Lalani, Wanling Xie, Dylan J. Martini et al. · Journal for ImmunoTherapy of Cancer · 2018 · 256 citations · Full text